| Serial Number | 79330538 |
| Word Mark | BERGENBIO |
| Filing Date | Friday, October 22, 2021 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, August 1, 2023 |
| Registration Number | 7123344 |
| Registration Date | Tuesday, August 1, 2023 |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, May 16, 2023 |
| Description of Mark | The mark consists of the stylized wording "BERGENBIO" to the right of a design of 6 shaded circles and one outlined hexagon arranged in an overall hexagonal shape. |
| Goods and Services | Drugs and pharmaceutical products for medical purposes, namely, medications for the treatment of cancer and severe respiratory infections; drugs and pharmaceutical products for medical purposes incorporating antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors, or selective inhibitors of cell surface proteins, namely, medications for the treatment of cancer and severe respiratory infections; drugs and pharmaceutical products for medical purposes, for use in oncology and for the treatment of cancers, lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for medical purposes; diagnostic test kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for medical laboratory analysis; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease testing, namely, the testing for lung cancer, leukaemia, aggressive cancers, immune evasive cancers, metastatic cancers and severe respiratory infections; antibodies, small molecules and proteins for medical purposes; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for medical purposes; protein synthesis inhibitors for medical purposes |
| Goods and Services | Chemical preparations, chemical compounds, biochemical preparations and biologic compounds for scientific or industrial purposes, or for use in laboratories or in research; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for analytical and diagnostic purposes in laboratory use; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for the experimental production of drugs, pharmaceutical products and biotechnological preparations; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely, the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; chemical preparations, chemical compounds, biochemical preparations and biologic compounds for use in the development and manufacture of drugs and pharmaceutical products, namely, drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; active chemical and biochemical ingredients and components for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely, for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, small molecules and proteins for scientific or industrial purposes, or for use in laboratories or in research; antibodies, small molecules and proteins for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely, for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, small molecules and proteins for use in the development and manufacture of drugs and pharmaceutical products, namely, drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for scientific or industrial purposes, or for use in laboratories or in research; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of diagnostic products and services, drugs and pharmaceutical products, namely, for the diagnosis and treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; antibodies, anti-axl antibodies, small molecules, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins for use in the development and manufacture of drugs and pharmaceutical products, namely, drugs and pharmaceutical products that target axl, akt3 or other genes, proteins, kinases and enzymes; proteins for use in kinase inhibiting technology, for scientific purposes |
| Goods and Services | Drug discovery and pharmaceutical drug development services; scientific research services; research and development services in the fields of oncology and immunology; scientific research services related to the role of axl and related kinase signalling in disease; scientific research services related to axl biology and its role in mediating aggressive disease; scientific research services related to biomarker discovery; scientific research services related to the development of diagnostic products and services, in the field of treatment of cancers, including lung cancer, leukaemia, aggressive cancers, immune evasive cancers and metastatic cancers; scientific research services related to improving the efficacy of chemotherapy, targeted cancer therapy and immunooncology drugs; research and development services in the field of antibodies, small molecules and proteins; conducting and providing research and development services for others in the field of antibody and small molecule technology; medical and biotechnology research services; research, development and engineering of antibodies, small molecules and proteins, namely, anti-axl antibodies, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins; laboratory research services relating to the production of antibodies, small molecules and proteins, namely, anti-axl antibodies, small molecules that inhibit axl kinase, selective inhibitors, selective axl inhibitors, selective axl kinase inhibitors and selective inhibitors of cell surface proteins; researching and developing the use of antibodies, small molecules and proteins for the treatment of patients; information, consultancy and advisory services related to the aforesaid services |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, January 7, 2022 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, January 7, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, January 7, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | BerGenBio ASA |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 63 - NOT AVAILABLE |
| Address | NO |
| Party Name | BerGenBio ASA |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 63 - NOT AVAILABLE |
| Address | NO |
| Party Name | BerGenBio ASA |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 63 - NOT AVAILABLE |
| Address | NO |
| Event Date | Event Description |
| Tuesday, November 21, 2023 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Wednesday, November 1, 2023 | FINAL DISPOSITION NOTICE SENT TO IB |
| Wednesday, November 1, 2023 | FINAL DISPOSITION PROCESSED |
| Wednesday, November 1, 2023 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Tuesday, August 1, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, August 1, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Sunday, June 25, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB |
| Wednesday, June 7, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, June 7, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Wednesday, May 17, 2023 | NOTIFICATION PROCESSED BY IB |
| Tuesday, May 16, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, May 16, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, April 26, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, April 26, 2023 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, April 26, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, April 10, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, April 5, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, April 5, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, April 5, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, March 28, 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, March 28, 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, March 28, 2023 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, March 28, 2023 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, March 28, 2023 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, February 28, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, February 28, 2023 | NON-FINAL ACTION E-MAILED |
| Tuesday, February 28, 2023 | NON-FINAL ACTION WRITTEN |
| Sunday, February 5, 2023 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Thursday, January 26, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, January 26, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, January 26, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, January 24, 2023 | REFUSAL PROCESSED BY IB |
| Wednesday, January 4, 2023 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Wednesday, January 4, 2023 | REFUSAL PROCESSED BY MPU |
| Tuesday, October 18, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Monday, October 17, 2022 | NON-FINAL ACTION WRITTEN |
| Tuesday, October 11, 2022 | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW |
| Tuesday, October 11, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, October 11, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, October 11, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, October 11, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, October 11, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Tuesday, August 9, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Monday, August 8, 2022 | NON-FINAL ACTION WRITTEN |
| Monday, August 1, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, May 17, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, May 17, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, May 17, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, May 17, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, May 17, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Saturday, March 5, 2022 | NEW REPRESENTATIVE AT IB RECEIVED |
| Tuesday, January 11, 2022 | APPLICATION FILING RECEIPT MAILED |
| Friday, January 7, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, January 6, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |